

Tecfidera (dimethyl fumarate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year, unless otherwise noted below

Medications	Quantity Limit
Tecfidera (dimethyl fumarate) Starter Kit – brand and generic	1 pack per fill, one time fill (30 day supply)
Tecfidera (dimethyl fumarate) 120mg delayed release capsules - brand and generic	14 capsules per fill, one time fill (starting dose, 7 day supply)
Tecfidera (dimethyl fumarate) 240mg delayed release capsules - brand and generic	2 capsules per day (maintenance dose)

APPROVAL CRITERIA

Requests for **brand and generic** Tecfidera (dimethyl fumarate) may be approved when the following criterion is met:

- I. Individual has a diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease)

Requests for **brand** Tecfidera must also meet the following criterion, in addition to the above Prior Authorization criteria:

- I. Documentation is provided that individual has had a trial of dimethyl fumarate (generic Tecfidera). Medication samples/coupons/discount cards are excluded from consideration as a trial.; **AND**
- II. Documentation is provided that individual was unable to tolerate dimethyl fumarate (generic Tecfidera).

Tecfidera (dimethyl fumarate) may not be approved for the following:

- I. Use in combination with other MS disease modifying agents (including Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone/Glatiramer/Glatopa, Extavia, Gilenya, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Plegridy, Ponvory, Rebif, Tascenso ODT, Tyruko, Tysabri, Vumerity and Zeposia); **OR**
- II. Individual is using to treat non-active secondary progressive multiple sclerosis.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 27, 2023.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Feuerstein JD, Issacs KL, Schneider Y, et al. American Gastroenterological Association Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology* 2020; 158:1450-1461.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Olek MJ, Howard J. Clinical presentation, course and prognosis of multiple sclerosis in adults. Last updated: August 30, 2023. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: October 19, 2023.
6. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90: 777-788. Available from: <https://www.aan.com/Guidelines/home/GuidelineDetail/898>. Accessed: October 27, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.